Luteolin in Non-Alcoholic Fatty Liver Disease (NAFLD): Bridging Preclinical Promise to Clinical Challenges
Received Date: Jun 28, 2024 / Published Date: Apr 09, 2025
Abstract
Non-Alcoholic Fatty Liver Disease (NAFLD) has emerged as a significant global health issue, necessitating effective therapeutic strategies. Luteolin, a flavonoid abundant in various plants, shows potential in preclinical NAFLD models due to its diverse pharmacological properties. This comprehensive review consolidates current knowledge on Luteolin's potential benefits, acknowledges gaps in research, and proposes strategies for advancing its clinical application. Key areas of focus include Luteolin's impacts on hepatic lipid metabolism, inflammation, oxidative stress, and its pharmacokinetic limitations. The review emphasizes the necessity of rigorous clinical trials to confirm its effectiveness and safety in human NAFLD populations.
Keywords: Luteolin; Non-Alcoholic Fatty Liver Disease (NAFLD); Hepatic lipid metabolism; Autophagy;Apoptosis; Natural compounds; Clinical translation
Citation: Qin R (2025) Luteolin in Non-Alcoholic Fatty Liver Disease (NAFLD):Bridging Preclinical Promise to Clinical Challenges. J Obes Weight Loss Ther 15:791.
Copyright: © 2025 Qin R. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
Select your language of interest to view the total content in your interested language
Share This Article
Recommended Journals
Open Access Journals
Article Usage
- Total views: 380
- [From(publication date): 0-0 - Apr 05, 2026]
- Breakdown by view type
- HTML page views: 254
- PDF downloads: 126
